FindTrial
Sign In

Intervention1: IRL-1620 For Injection (PMZ-1620): PMZ-1620 + Standard of care: Three doses of PMZ-1620, at 0.3 μg/kg body weight will be administered as an intravenous bolus over 1 minute every 3 hou

2 trials

Sponsors

Pharmazz India Private Limited

Conditions

Health Condition 1: S141- Other and unspecified injuries ofcervical spinal cord Health Condition 2: S241- Other and unspecified injuries ofthoracic spinal cord Health Condition 3: S341- Other and unspecified injury of lumbar and sacral spinal cordHealth Condition 1: null- Acute Ischemic Stroke Health Condition 2: I635- Cerebral infarction due to unspecified occlusion or stenosis of cerebral arteries

Phase 2

To Study the effect of PMZ-1620 in stroke patients.
Active, not recruitingCTRI/2017/11/010654
Pharmazz India Private LimitedHealth Condition 1: null- Acute Ischemic Stroke Health Condition 2: I635- Cerebral infarction due to unspecified occlusion or stenosis of cerebral arteries
Target: 40Updated: 2023-03-06
To Study the effect of PMZ-1620 in spinal cord injury patients.
Active, not recruitingCTRI/2018/12/016667
Pharmazz India Private LimitedHealth Condition 1: S141- Other and unspecified injuries ofcervical spinal cord Health Condition 2: S241- Other and unspecified injuries ofthoracic spinal cord Health Condition 3: S341- Other and unspecified injury of lumbar and sacral spinal cord
Target: 40Updated: 2022-11-21

Related Papers

Efficacy and Safety of Sovateltide in Patients with Acute Cerebral Ischaemic Stroke: A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Phase III Clinical Trial
Drugs2024-11-153 citations
Safety and Efficacy of Sovateltide (IRL-1620) in a Multicenter Randomized Controlled Clinical Trial in Patients with Acute Cerebral Ischemic Stroke.
2021-01-1129 citations
Abstract 14: A Randomized Study to Determine Efficacy of Sovateltide (PMZ-2010) in Patients With Acute Cerebral Ischemic Stroke
Stroke2020-02-01